0001415889-24-008771.txt : 20240320 0001415889-24-008771.hdr.sgml : 20240320 20240320180025 ACCESSION NUMBER: 0001415889-24-008771 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240318 FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gillies Hunter CENTRAL INDEX KEY: 0001868997 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 24768833 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-03202024_060312.xml X0508 4 2024-03-18 0001798749 Aerovate Therapeutics, Inc. AVTE 0001868997 Gillies Hunter C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false CHIEF MEDICAL OFFICER 1 Common Stock 2024-03-18 4 M 0 4000 1.74 A 7251 D Common Stock 2024-03-18 4 M 0 3000 2.14 A 10251 D Common Stock 2024-03-18 4 S 0 6387 25.8137 D 3864 D Common Stock 2024-03-18 4 S 0 613 26.4022 D 3251 D Stock Option (Right to Buy) 1.74 2024-03-18 4 M 0 4000 0 D 2030-09-03 Common Stock 4000 4036 D Stock Option (Right to Buy) 2.14 2024-03-18 4 M 0 3000 0 D 2031-04-01 Common Stock 3000 98510 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.25 to $26.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. /s/ George A. Eldridge, Attorney-in-Fact 2024-03-20